Physician profile
Mandeep Kaur
NPI 1215298856
$2,178.11
in general payments reported to CMS, 2019-2025
18 companies · $55.72 in 2025
The $55.72 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $177 · 2021: $1,082 · 2022: $81.27 · 2025: $55.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $55.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $55.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $286.48 | 2019-2022 | |
| Alkermes, INC. | $244.52 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $200.15 | 2021 | |
| Abbvie INC. | $190.29 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $178.18 | 2019-2021 | |
| Lundbeck LLC | $178.08 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $155.14 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $125.62 | 2020-2021 | |
| Allergan, INC. | $122.55 | 2019-2020 | |
| Indivior INC. | $113.19 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $90.12 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $75.04 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.61 | 2020-2021 | |
| Shire North American Group INC | $54.36 | 2019 | |
| Ironshore Pharmaceuticals INC. | $35.49 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.04 | 2021 | |
| Neos Therapeutics, LP | $21.19 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.